#### IV model

With the drug-specific parameters fixed, the healthy PBPK model was translated to a HI-PBPK model. Stages of HI used in the simulations were defined by the Child-Pugh score. Two PK studies, Macgilchrist, Birnie (42) and Pentikäinen, Välisalmi (43), were used to evaluate the HI-PBPK model with IV administration (**Table 2**). 

A population with Child-Pugh A, B, and C was created according to the patient demographics of the population enrolled by Macgilchrist, Birnie (42). Similarly, a population with Child-Pugh B and C was created according to the patient demographics of the population enrolled by Pentikäinen, Välisalmi (43). The Child-Pugh scores were not defined in these studies, and thus reported information such as plasma albumin concentrations, total bilirubin, etc. were used to classify. 

**Table 2. HI population demographics for midazolam IV administration**

| **Study** | **Dose and administration** | **Cohort** | **N** | **Age (years)** | **Weight (kg)** |
|--|--|--|--|--|--|
| Macgilchrist, Birnie (42) | 0.075 mg/kg IV bolus | European patients with estimated Child-Pugh scores A-C | 7 | 39-54 | 71.3 ± 4.3 |
| Pentikäinen, Välisalmi (43) | 7.5 mg IV bolus | European male patients with estimated Child-Pugh scores B and C | 7 | 48 ± 13.9 | 85.1 ± 12.2 |

Simulated PK of midazolam administered as a 0.075 mg/kg IV bolus in patients with Child-Pugh A, B, and C are presented in **Figure 1**, **Figure 2**, and **Figure 3**, respectively. An evaluation of predicted versus observed PK parameters from patients enrolled in Macgilchrist, Birnie (42) is presented in **Table 3**. 

**Table 3. Evaluation of midazolam IV HI-PBPK model-predicted vs observed PK parameters from Macgilchrist, Birnie (42)**

| **Study** | **Predicted clearance (mL/min/kg)** | **Observed clearance (mL/min/kg)** | **Fold-error** | **Predicted half-life (h)** | **Observed half-life (h)** | **Fold-error** | 
|--|--|--|--|--|--|--|
| Macgilchrist, Birnie (42), control | 6.3 | 10.4 ± 1.3 | 0.61 | 2.67 | 1.6 ± 0.3 | 1.67 |
| Macgilchrist, Birnie (42), HI population | Child-Pugh A: 4.85; B: 2.93; C: 1.85 | 5.4 ± 1 | A: 0.89; B: 0.54; C: 0.34 | A: 3.58; B: 5.64; C: 10.5 | 3.9 ± 0.8 | A: 0.92; B: 1.45; C: 2.69 |

Simulated PK of midazolam administered as a 7.5 mg IV bolus in patients with Child-Pugh B and C are presented in **Figure 3** and **Figure 4**, respectively. An evaluation of predicted versus observed AUC<sub>∞</sub> and clearance from patients enrolled in Pentikäinen, Välisalmi (43) is presented in **Table 4**. 

**Table 4. Evaluation of midazolam IV HI-PBPK model-predicted predicted vs observed AUC<sub>∞</sub> and clearance from Pentikäinen, Välisalmi (43)**

| **Study** | **Predicted AUC<sub>∞</sub> (µg•h/L)** | **Observed AUC<sub>∞</sub> (µg•h/L)** | **Fold-error** | **Predicted clearance (mL/min/kg)** | **Observed clearance (mL/min/kg)** | **Fold-error** |
|--|--|--|--|--|--|--|
| Pentikäinen, Välisalmi (43), control | 296.61 | 298 ± 25 | 0.99 | 5.81 | 5.63 ± 0.43 | 1.04 |
| Pentikäinen, Välisalmi (43), HI population | Child-Pugh B: 698.45; C: 1171.57 | 543 ± 93 | B: 1.29; C: 2.16 | B: 2.35; C: 1.54 | 3.34 ± 0.6 | B: 0.7; C: 0.46 |

#### Oral model

Two studies, Pentikäinen, Välisalmi (43) and Andersen, Pedersen (44), were used to evaluate the HI-PBPK model with oral administration (**Table 5**). Unlike Macgilchrist, Birnie (42) and Pentikäinen, Välisalmi (43), Andersen, Pedersen (44) categorized their patients based on Child-Pugh scores A-C. 

**Table 5. HI population demographics for midazolam oral administration**

| **Study** | **Dose and administration** | **Cohort** | **N** | **Age (years)** | **Weight (kg)** |
|--|--|--|--|--|--|
| Pentikäinen, Välisalmi (43) | 15 mg oral single dose 3 days after receiving IV bolus | European male patients with estimated Child-Pugh scores B and C | 7 | 48 ± 13.9 | 85.1 ± 12.2 |
| Andersen, Pedersen (44) | 15 mg oral single dose | European females (30%) and males with Child-Pugh A-C | A: 6; B: 1; C: 3 | 30-79 | Not reported |

Simulated PK of midazolam administered as a 15 mg oral single dose in patients with Child-Pugh B and C are presented in **Figure 4** and **Figure 5**, respectively. An evaluation of predicted versus observed AUC<sub>∞</sub> and Cmax from patients enrolled in Pentikäinen, Välisalmi (43) is presented in **Table 6**. 

**Table 6. Evaluation of midazolam oral HI-PBPK model-predicted predicted vs observed AUC<sub>∞</sub> and Cmax from Pentikäinen, Välisalmi (43)**

| **Study** | **Predicted AUC<sub>∞</sub> (µg•h/L)** | **Observed AUC<sub>∞</sub> (µg•h/L)** | **Fold-error** | **Predicted Cmax (µg/L)** | **Observed Cmax (µg/mL)** | **Fold-error** |
|--|--|--|--|--|--|--|
| Pentikäinen, Välisalmi (43), control | 260.9 | 362 ± 61 | 0.72 | 70.69 | 90 ± 14 | 0.79 |
| Pentikäinen, Välisalmi (43), HI population | Child-Pugh B: 880.49; C: 1289.16 | 576 ± 89 | B: 1.53; C: 2.24 | B: 76.96; C: 54.04 | 129 ± 24 | B: 0.59; C: 0.41 |

Finally, an evaluation of predicted versus observed AUC<sub>∞</sub> and Cmax from patients enrolled in Andersen, Pedersen (44) is presented in **Table 7**. 

**Table 7. Evaluation of midazolam oral HI-PBPK model-predicted predicted vs observed AUC<sub>∞</sub> and Cmax from Andersen, Pedersen (44)**

| **Study** | **Predicted AUC<sub>∞</sub> (µg•h/L)** | **Observed AUC<sub>∞</sub> (µg•h/L)** | **Fold-error** | **Predicted Cmax (µg/L)** | **Observed Cmax (µg/mL)** | **Fold-error** |
|--|--|--|--|--|--|--|
| Andersen, Pedersen (44), HI population | Child-Pugh A: 19507.72; B: 65209.07; C: 79644.66 | 24700 | A: 0.79; B: 2.64; C: 3.22 | A: 57.92; B: 97.06; C: 56.21 | 87 | A: 0.67; B: 1.12; C: 0.65 |